Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes various ...

If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.

Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for ...

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...

An Insilico Medicine drug candidate spawned by the company’s artificial intelligence technology now has clinical data showing breathing improvement in patients who have a debilitating lung disorder.

PPF is identified by decline in lung function, worsening symptoms, and increased fibrosis on imaging, with variable criteria across studies. Risk factors for PPF include older age, male sex, smoking, ...

Upright area-detector CT is equal to or better than supine ADCT in detecting the loss in lung function and assessing the severity of PPF.